Clusterin CSF levels in differential diagnosis of neurodegenerative disorders
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26810527
DOI
10.1016/j.jns.2015.12.023
PII: S0022-510X(15)30089-7
Knihovny.cz E-zdroje
- Klíčová slova
- Alzheimer disease, CSF, Clusterin, Neurodegeneration, Parkinson's disease,
- MeSH
- biologické markery mozkomíšní mok MeSH
- diferenciální diagnóza MeSH
- klusterin mozkomíšní mok MeSH
- lidé středního věku MeSH
- lidé MeSH
- neurodegenerativní nemoci mozkomíšní mok diagnóza MeSH
- proteiny tau mozkomíšní mok MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- biologické markery MeSH
- klusterin MeSH
- proteiny tau MeSH
INTRODUCTION: Clusterin, a heterodimeric glycoprotein, is thought to be involved in many cellular functions, including cell-cell interaction, cell survival and apoptosis. In the brain, post-mortem analysis has found increased clusterin associated with the pathology of many other neurodegenerative diseases (ND) such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD) and multiple system atrophy (MSA). In vivo cerebrospinal fluid (CSF) levels of clusterin in ND diseases may reflect differences in the pathology and thus aid in the differential diagnosis. METHODS: CSF levels of clusterin were assessed in 102 patients with clinical manifestations of neurodegenerative diseases (23 patients with PD, 18 with PDD, 15 with DLB, 18 with AD, 16 with PSP, 12 with MSA) and 21 subjects as a control group (CG). RESULTS: Significantly higher CSF clusterin levels were found in PD compared to CG (median 6884 vs. 4484; p=0.012), DLB (median 6884 vs. 4192; p=0.023), MSA (median 6884 vs. 3606; p=0.001) and PSP (median 6884 vs. 4193; p=0.014). Significantly higher CSF clusterin levels were found in PDD compared to CG (median 8617 vs. 4484; p=0.045), DLB (median 8617 vs. 4192; p=0.025) and MSA (median 8617 vs. 3606; p=0.004). CONCLUSION: The results of the presented "feasibility" study support the role of clusterin in PD/PDD pathogenesis. Clusterin CSF levels could serve as a potential marker for PDD and DLB differentiation.
Citace poskytuje Crossref.org
Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis
Metabolic Syndrome, Clusterin and Elafin in Patients with Psoriasis Vulgaris
